CClinicalTrials.gg
WithdrawnNCT04346511Amp-HTNUpdated Nov 30, 2023

Acupuncture Treatment on Cerebral Blood Flow

A Phase 2 interventional study of Acupuncture in High Blood Pressure, sponsored by University of Oklahoma. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-30.

Sponsored by University of Oklahoma · Phase 2, Interventional, and Basic science

Why this study was withdrawn
Never initiated - KSP lost interest
Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Cerebrovascular diseases (CVD) and neurodegenerative diseases (NDD) are both leading causes of death in the United States. Epidemiological data have shown that increased prevalence of hypertension is related to these outcomes. However, despite the strong association of poor brain health outcomes in patients with hypertension (HTN), the understanding of cerebral blood flow (CBF) regulation and treatment options for HTN remain limited. Acupuncture treatment (AT), which is considered a promising complementary and integrative modality, has been known to reduce blood pressure and improve endothelial function in HTN. However, very few studies have investigated AT's effect on cerebrovascular function and the possible neuroprotective properties directly via regulating HTN. Exercise is used as a stimulus that increases the brain's metabolism and requires cerebrovascular responses (vasodilation) to meet the new metabolism.

Therefore, the specific aim of this study is to test the hypothesis that an antihypertensive acupuncture treatment can acutely improve cerebrovascular responses in hypertensive humans during moderate exercise.

Read the detailed description

After IRB approval, experiments will take place in the Human Circulation Research Laboratory in the Department of Health and Exercise on the OU Norman campus. All subjects will complete a total of 3 visits. The first is a screening visit to provide informed consent and to ensure the potential participant meets all inclusion criteria and no exclusion criteria. Once enrolled, participants will complete two experimental trials (Placebo (PL, Sham Acupuncture) or Real Acupuncture (RA), randomized) in a single-blinded crossover design. PL or RA treatment will precede testing by \~25min before to maximize acute responses. Test begins with 5 min of quiet rest where baseline measurements are taken, followed by 5 min of exercise. After exercise, subjects will be given 5 min of quiet rest.

Visit 1 (Screening day): \~1.5 hours. The screening visit will include informed consent, health history, physical activity questionnaires and blood sample. If qualified, the subject will be enrolled in the study and they will complete a maximal oxygen uptake (VO2max) cycle ergometer test to determine fitness.

Visit 2 \& 3 (Study day): \~1.5 hours. Instrumentation: Subjects will be equipped with ECG for heart rate (HR), photoplethysmography for blood pressure, pulse oximeter, mouthpiece for end-tidal CO2 (PETCO2) and oxygen uptake (VO2), near-infrared spectroscopy (NIRS) for active muscle oxygenation and Transcranial Doppler (TCD) for CBF. Real Acupuncture (RA): Subjects will receive \~20 minutes of RA treatment prior to exercise. Placebo (PL): Specially designed Sham Acupuncture needles will be used in the same acupoints, for the same duration as RA.

All subjects will complete a total of 3 visits separated by a minimum of 48 hours. Each study visit will take \~1.5 hours. The investigators anticipate \~ 6 hours or less of total involvement of the participants' time.

This study is a single-blind crossover design. Participants will be blinded in two trials. Practitioners and operators will not be allowed to communicate with the participants concerning the type of acupuncture devices. Outcome assessors and statisticians may not be blinded to treatment allocation.

The key dependent variable of interest is change (delta) in cerebrovascular conductance index (CVCi = CBF/blood pressure) from rest to exercise (delta CVCi = CVCiExercise - CVCiRest). Delta CVCi is the most common assessment of vasodilation in humans as it normalizes differences in blood flow to differences in blood pressure. CVCi calculates how much blood flow is observed for a given pressure. A change in CVCi (delta CVCi) has a predictable relationship where + delta CVCi indicates vasodilation (more flow for a given pressure) and - delta CVCi indicates vasoconstriction (less flow for a given pressure). Data will be analyzed using a general linear model approach (similar to ANOVA). Based on pilot data, a total sample size of 40 (20 CON and 20 HTN) will provide a power of 0.9. A minimum of 60 participants will be to recruited to ensure statistical power is achieved.

02

Conditions studied

  • High Blood Pressure

Browse trials for

03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

Browse Hypertension studies →

Lead sponsor

University of Oklahoma is the lead sponsor of 424 studies on the registry; 99 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 16 (38%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Subjects will include healthy controls (CON) and Hypertension (HTN) patients between 18-65 years of age. Female participants if premenopausal will be studied in the early follicular phase of their cycle to minimize vascular effects of circulating hormones.

HTN:

  1. Stage 1 hypertensive, Systolic BP (SBP) ≥ 130 mmHg and/or Diastolic BP (DBP) > 80 mmHg, and/or diagnosis of HTN, with BMI and physical activity levels ≈ CON
  1. If they are on anti-hypertensive medication, the dose, type, and frequency of use will be recorded.
  2. HTN with an SBP > 139 mmHg must have a medical doctor's permission to participate

CON: will be age, BMI, menstrual status for females, and physical activity matched to HTN. They must be:

  1. Normotensive
  2. Free of cardiovascular comorbidities.

Exclusion criteria

Exclusion Criteria:

  1. Diabetes
  2. Coronary artery disease
  3. Stroke
  4. Heart attack
  5. Sleep apnea
  6. Tobacco use
  7. Asthma
  8. Pregnancy
  9. Currently receiving antihypertensive acupuncture treatment
  10. conditions where acupuncture might not be safe, such as metal allergy or needle-phobia. If a subject experiences severe acupuncture-associated response, it will be subject to early termination of the study.
05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Acupuncture

    In a supine position with a cardboard blocking view of their legs, patients will have six, 0.25\*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal. After which the needles will be removed.

    Other: Acupuncture

  • Sham comparator
    Sham Acupuncture

    Specially designed Sham acupuncture needles that are not actually penetrate the skin and activate the acupoint will be used in an identical procedure to RA. The patient would be able to feel light pressure at the site.

    Other: Acupuncture

Interventions

  • OtherAcupuncture

    Patients will have six, 0.25\*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal.

    Also known as: Sham Acupuncture

06

What researchers measure

Primary outcomes

  1. Cerebrovascular Conductance Index

    Middle Cerebral Artery Blood Velocity relative to Mean Arterial Pressure (MCABV/MAP)

    Time frame: 5 min of moderate exercise

  2. Middle cerebral artery blood velocity

    Velocity of blood through the middle cerebral arteries

    Time frame: 5 min of moderate exercise

  3. Mean Arterial Pressure

    Integral of blood pressure waveform

    Time frame: 5 min of moderate exercise

Secondary outcomes

  1. Heart Rate Variability

    measure of the variation in time between each heartbeat

    Time frame: before and after acupuncture

  2. End-tidal CO2

    Partial pressure carbon dioxide (CO2) at the end of an exhaled breath

    Time frame: 5 min of moderate exercise

  3. Oxygen Uptake

    Volume of oxygen consumed by the body per minute

    Time frame: 5 min of moderate exercise

  4. peripheral capillary oxygen saturation

    estimate of the amount of oxygen in the blood

    Time frame: 5 min of moderate exercise

  5. Tissue saturation index

    estimate of the amount of oxygen in muscle

    Time frame: 5 min of moderate exercise

  6. blood glucose levels

    venous blood content

    Time frame: prior to enrollment

  7. blood triglyceride levels

    venous blood content

    Time frame: prior to enrollment

  8. blood high density lipoprotein levels

    venous blood content

    Time frame: prior to enrollment

  9. blood low density lipoprotein levels

    venous blood content

    Time frame: prior to enrolment

07

Study locations

1 site
  • Department of Health and Exercise Science
    Norman, Oklahoma 73019, United States
08

References and documents

Individual participant data

Plan to share: No — No: There is not a plan to make IPD available.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04346511
Lead sponsor
University of Oklahoma
Responsible party
Sponsor
First posted
Apr 15, 2020
Start date
May 9, 2020
Primary completion
Dec 5, 2022
Completion
Dec 5, 2022
Last update
Nov 30, 2023

Study contacts

Jeremy M Kellawan, PhD
principal investigator · University of Oklahoma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion